•
Jun 30, 2021

Zimmer Biomet Q2 2021 Earnings Report

Reported financial results for the second quarter of 2021.

Key Takeaways

Zimmer Biomet's second quarter net sales were $2.027 billion, an increase of 65.3% over the prior year period, and an increase of 60.7% on a constant currency basis. Second quarter 2021 net sales increased 1.9% when compared to the pre-pandemic second quarter 2019, and were flat on a constant currency basis. Net earnings for the second quarter of 2021 were $141.9 million, or $400.5 million on an adjusted basis. Diluted earnings per share were $0.67 for the second quarter and adjusted diluted earnings per share were $1.90.

Second quarter net sales of $2.027 billion increased 65.3%, 60.7% on a constant currency basis

Second quarter net sales of $2.027 billion increased 65.3%, 60.7% on a constant currency basis

Second quarter diluted earnings per share were $0.67; adjusted diluted earnings per share were $1.90

Company updates 2021 financial guidance, narrowing range for full year outlook

Total Revenue
$2.03B
Previous year: $1.23B
+65.3%
EPS
$1.9
Previous year: $0.05
+3700.0%
Gross Profit
$1.45B
Previous year: $802M
+80.3%
Cash and Equivalents
$1.04B
Previous year: $713M
+46.1%
Free Cash Flow
$425M
Previous year: -$145M
-392.3%
Total Assets
$24.2B
Previous year: $23.6B
+2.4%

Zimmer Biomet

Zimmer Biomet

Zimmer Biomet Revenue by Segment

Zimmer Biomet Revenue by Geographic Location

Forward Guidance

The Company is updating its full-year 2021 financial guidance to narrow its previous projected ranges for revenue growth and adjusted diluted EPS:

Positive Outlook

  • 2021 reported revenue growth: 14.5% - 16.5%.
  • Foreign Currency Exchange Impact: 1.5%
  • Adjusted Operating Profit Margin: 26.5% - 27.0%
  • Adjusted Tax Rate: 16.0% - 16.5%
  • Adjusted Diluted EPS: $7.65 - $7.95

Revenue & Expenses

Visualization of income flow from segment revenue to net income